NASDAQIndustrialsSpecialty Business ServicesSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 44.7M |
| EPS | — | 1.02 |
Management figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress on deepening customer relationships | Harte Hanks aims to deepen customer relationships to drive growth. | Improving | progress score remains below 40% next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Management emphasized deepening customer relationships to drive growth and long-term value in 2026. However, revenue declined from $41.6M in 2025-Q1 to $37.3M in 2026-Q1, reflecting pressure from legacy offerings and market headwinds. The trajectory shows persistent focus but limited revenue growth delivery so far. Delivery assessment Oct 24, 2026 |
Return to profitability | A primary condition in Harte Hanks Inc's published investment case. The stated target is positive net income and free cash flow in next 4 quarters. | Broken | net income and free cash flow remain negative beyond next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth stabilizes or improves | A primary condition in Harte Hanks Inc's published investment case. The stated target is >= -5% revenue growth next 4 quarters. | Broken | revenue growth falls below -5% next 4 quarters | Revenue growth: -1.67% FY2026-Q2; GAAP. Published target: >= -5% revenue growth next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 14, 2026-1.674821 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ad363d33-b67a-4f26-8f53-335596e9a6f5. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Management emphasized deepening customer relationships to drive growth and long-term value in 2026. However, revenue declined from $41.6M in 2025-Q1 to $37.3M in 2026-Q1, reflecting pressure from legacy offerings and market headwinds. The trajectory shows persistent focus but limited revenue growth delivery so far. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative turnaround thesis, not a proven durable compounder. The current thesis is on watch: the signal recently shifted from cautious to mixed, while financial performance remains weak and risk is high.
The valuation evidence points to HHS being cheap versus peers, but the model has low confidence and the expectations gap is negative. The priced-in tag is justified, with low fragility, so the evidence does not show that the valuation is unusually exposed to concentrated market expectations.
Near term, earnings risk is elevated after consecutive misses, and management's focus on customer relationships has not yet produced revenue growth; revenue fell from $41.6 million in 2025-Q1 to $37.3 million in 2026-Q1. Adjusted EBITDA also declined over that period, while cash was $4.5 million with no debt at 2026-Q1. The next-quarter outlook is uncertain, and the evidence flags a possible guidance cut as a key risk.
Over the next few quarters, the thesis hinges on management improving revenue and operating efficiency while preserving liquidity. Sector conditions are another swing factor: continued strength at CTAS, CPRT, and ROL could support the Industrials backdrop, while misses or lower guidance from those companies could weaken it.
For the next 1 to 3 years, HHS is a watch-stage turnaround with weak recent results and meaningful execution risk, partly balanced by a debt-free balance sheet and a valuation that is cheap versus peers. The thesis needs clearer evidence of growth and operating progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.